脑血管痉挛（CVS）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 美国市场预计将从约 1.02 亿美元成长到约 1.7 亿美元（年复合成长率约 5-6%）。
• 先进的重症监护和血管内治疗正在推动成长，而有针对性的药物创新却受到限制。

脑血管痉挛（CVS）概述

脑血管痉挛（CVS）是颅内动脉瘤破裂导致蜘蛛膜下腔出（aSAH）的严重且可能危及生命的併发症，其特征是颅内主要动脉延迟性狭窄。它通常在出血后3至14天发生，是导致患者发病率和死亡率的主要因素。

此病的病理生理机转是由蛛网膜下腔内红血球的破坏引发的。这会导致氧合血红素和其他致痫因子的释放，进而导致一氧化氮耗竭、神经发炎、氧化压力和血管重塑。这种连锁反应可导致脑血流量减少，最终发展为迟发性脑缺血（DCI），而迟发性脑缺血是神经系统预后不良的主要决定因素。

临床上，CVS表现为新发神经功能缺损、意识障碍及中风风险。诊断需密切监测，可采用经经颅都卜勒（TCD）和CT血管摄影检查，其中数位减影血管摄影检查（DSA）为黄金标准。

目前的标准治疗方案强调维持正常血液容积和预防诱发性高血压，以优化脑灌注。药物治疗方面，已证实具有神经保护作用的尼莫地平仍是核心治疗药物。对于难治性病例，可采用血管内治疗，包括动脉内血管扩张剂和球囊血管成形术，以恢復脑血流。

主要亮点

• CVS 是 aSAH 的常见併发症，源自于延迟性缺血的风险。
• 预计美国蛛网膜下腔出血 (aSAH) 的发生率将从约 36,100 例增加到约 39,400 例（年复合成长率约为 0.9%）。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Idorsia

目录

第一章：主要调查结果及分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物类别分類的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期管道

第六章：未满足的需求与目标产品分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Cerebral Vasospasm (CVS) Market Outlook

Thelansis's "Cerebral Vasospasm (CVS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebral Vasospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cerebral Vasospasm (CVS) Overview

Cerebral vasospasm (CVS) is a severe and potentially life-threatening complication of aneurysmal subarachnoid hemorrhage (aSAH), characterized by delayed narrowing of major intracranial arteries. It typically occurs between 3 to 14 days post-hemorrhage and is a major contributor to morbidity and mortality in affected patients.

The pathophysiology is driven by the breakdown of erythrocytes in the subarachnoid space, releasing oxyhemoglobin and other spasmogenic factors, which lead to depletion of nitric oxide, neuroinflammation, oxidative stress, and vascular remodeling. This cascade results in reduced cerebral blood flow, potentially progressing to delayed cerebral ischemia (DCI), a key determinant of poor neurological outcomes.

Clinically, CVS presents with new-onset neurological deficits, altered consciousness, and risk of cerebral infarction. Diagnosis requires close monitoring using transcranial Doppler (TCD) and CT angiography, with digital subtraction angiography (DSA) as the gold standard.

The current standard of care emphasizes maintenance of euvolemia and induced hypertension to optimize cerebral perfusion. Pharmacologically, nimodipine remains the cornerstone therapy due to its proven neuroprotective benefits. In refractory cases, endovascular interventions, including intra-arterial vasodilators and balloon angioplasty, are employed to restore cerebral blood flow.

Key Highlights

• CVS is a high-morbidity complication of aSAH, driven by delayed ischemia risk
• US aSAH incidence expected to increase from ~36.1K to ~39.4K (~0.9% CAGR)

Market Overview

• US market projected to grow from ~$102M to ~$170M (~5-6% CAGR)
• Growth driven by advanced critical care and endovascular interventions, with limited targeted pharmacologic innovation

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Idorsia

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)